3-rx.comCustomer Support
HomeAbout UsFAQContactHelp
News Center
Health Centers
Medical Encyclopedia
Drugs & Medications
Diseases & Conditions
Medical Symptoms
Med. Tests & Exams
Surgery & Procedures
Injuries & Wounds
Diet & Nutrition
Special Topics

\"$alt_text\"');"); } else { echo"\"$alt_text\""; } ?>

Join our Mailing List


You are here : 3-RX.com > Home > AIDS/HIV - Drug News -

Europe gives final approval to Pfizer HIV drug

AIDS/HIV • • Drug NewsSep 24, 07

Pfizer Inc said on Monday the European Commission had approved its AIDS drug called Celsentri, or Selzentry in the United States, the first in a new class of oral HIV medicines.

The drug—which is known generically as maraviroc—is the first designed to keep HIV, the virus that causes AIDS, from entering healthy immune cells. Older AIDS medicines attack the virus itself.

It works by blocking the CCR5 co-receptor that serves as a main doorway for the HIV virus into immune cells.

The green light from the European authorities had been expected after a panel of EU experts recommended the product in July. The medicine was also cleared by the U.S. Food and Drug Administration last month.

Celsentri is approved for use in patients who have tried other medicines and for whom a diagnostic test has confirmed their HIV strain is linked to the CCR5 receptor.

New York-based Pfizer is counting on new medicines such as Celsentri to help drive profits as several blockbusters lose patent protection and its top-selling Lipitor cholesterol treatment faces strong competition.

Industry analysts have projected annual Celsentri sales of about $500 million by 2011.

Print Version
comments powered by Disqus

  New biomarkers may influence drug design and alternative treatments of cancer, study shows
  UGA ecologist finds another cause of antibiotic resistance
  New drug for neuroblastoma shows promise in phase I study
  Baclofen shows promise in patients with alcohol-induced liver disease
  Hepatitis C more prevalent than HIV/AIDS or Ebola yet lacks equal attention
  Cell-associated HIV mucosal transmission: The neglected pathway
  Findings point to an ‘off switch’ for drug resistance in cancer
  Offering option of initial HIV care at home increases use of ART
  Stopping statins may benefit terminally ill patients
  Cholesterol drug users may use pills as a license to overeat
  Pfizer lung cancer drug beats chemo for previously untreated patients
  Mass. General study identifies path to safer drugs for heart disease, cancer


Home | About Us | FAQ | Contact | Advertising Policy | Privacy Policy | Bookmark Site